Pluristem Therapeutics' PLX placental cells have been designated an orphan-disease treatment by the FDA as a therapy for aplastic anemia. "Receiving orphan drug designation for aplastic anemia is an important event for Pluristem as it open pathways for using our PLX cells for additional indications in the field of hematology," said Zami Aberman, Pluristem's chairman and CEO.

Full Story:
Globes (Israel)

Related Summaries